natgillin/translations-raw huggingface dataset:
Men hvis De ikke har taget Trevaclyn i 7 dage eller mere i træk, skal De tale med lægen, før De igen begynder at tage Trevaclyn. 
However, if you do not take Trevaclyn for 7 or more days in a row, talk to your doctor before restarting Trevaclyn.
Denne indlægsseddel blev senest ændret {MM/YYYY} 
This leaflet was last revised in {MM/YYYY}.
Hvis patienten har undladt at tage Trevaclyn i færre end 7 på hinanden følgende dage, kan behandlingen genoptages ved den senest administrerede dosis. 
If Trevaclyn is missed for less than 7 consecutive days, patients can resume therapy at the last administered dose.
Beslutning om, hvorvidt amningen eller behandlingen skal fortsætte/ophøre, bør tages i forhold til den gavnlige virkning af amning for barnet og den gavnlige virkning af Trevaclyn for kvinden. 
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Trevaclyn to the woman.
Indtagelse af alkohol eller varme drikke eller krydret mad kan forstærke flushing-effekten og bør derfor undgås omkring tidspunktet for indtagelse af Trevaclyn. 
Drinking alcohol or hot drinks or eating spicy foods can enhance the effects of flushing and should therefore be avoided around the time of ingestion of Trevaclyn.
• Lægen vil måske også tage blodprøver af og til, efter De er begyndt at tage Trevaclyn for at kontrollere, hvor godt Deres lever virker, og om der er andre bivirkninger. 
• Your doctor may also want you to periodically have blood tests after you start taking Trevaclyn, to check how well your liver is working and for other side effects.
Trevaclyn var konsekvent effektivt på tværs af alle på forhånd specificerede patientundergrupper i henhold til race, køn, LDL-C, HDL-C og TG ved baseline, alder og diabetesstatus. 
Trevaclyn was consistently efficacious across all prespecified patient subpopulations defined by race, gender, baseline LDL-C, HDL-C and TG levels, age and diabetes status.
Trevaclyn er ikke undersøgt hos børn og unge under 18 år. 
Trevaclyn has not been studied in children and adolescents who are under 18 years of age.
I kliniske undersøgelser har mere end 2.500 patienter fået Trevaclyn alene eller sammen med en HMG-CoA-reduktasehæmmer. 
In clinical trials, over 5,700 patients received Trevaclyn alone or with an HMG-CoA reductase inhibitor.
Trevaclyn indeholder nicotinsyre, som i terapeutiske doser er et lipidmodificerende stof, og laropiprant, der er en potent, selektiv prostaglandin D2-antagonist (PGD2) receptorsubtype 1 (DP1). 
Trevaclyn contains nicotinic acid, which at therapeutic doses is a lipid-modifying agent, and laropiprant, a potent, selective antagonist of the prostaglandin D2 (PGD2) receptor subtype 1 (DP1).
• At tage acetylsalicylsyre før De tager Trevaclyn vil ikke mindske Deres rødmen mere, end hvis De tager Trevaclyn alene. 
• Taking aspirin before you take Trevaclyn does not reduce your flushing more than taking Trevaclyn alone.
Som med andre nicotinsyrepræparater bør der udvises forsigtighed, når Trevaclyn anvendes til patienter med ustabil angina eller patienter i den akutte fase af myokardieinfarkt, især når disse patienter også får vasoaktive lægemidler, såsom nitrater, calciumkanalblokkere eller adrenerge blokkere. 
As with other nicotinic acid medicinal products, caution should be used when Trevaclyn is used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive medicinal products such as nitrates, calcium channel blockers, or adrenergic blocking agents.
For at bevare egenskaberne ved den modificerede udløsning må tabletterne ikke deles, brydes, knuses eller tygges, før de sluges. 
To preserve the modified-release properties, the tablets must not be split, broken, crushed, or chewed before swallowing.
Indehaveren af markedsføringstilladelsen skal udføre de lægemiddelovervågningsaktiviteter, som er beskrevet i lægemiddelovervågningsplanen (ifølge aftalen i RMP modul 1.8.2 i markedsføringstilladelsen), og enhver efterfølgende opdatering af RMP, som er godkendt af Udvalget for Lægemidler til Mennesker (CHMP). 
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP).
Navn og adresse på fremstilleren(fremstillerne) ansvarlig(e) for batchfrigivelse 
Name and address of the manufacturer(s) responsible for batch release
Hvis De har glemt at tage Trevaclyn 
If you forget to take Trevaclyn
INFORMATION I BRAILLESKRIFT Trevaclyn 
INFORMATION IN BRAILLE Trevaclyn
Da nicotinsyre og dets metabolitter udskilles via nyrerne, bør Trevaclyn anvendes med forsigtighed hos patienter med nyreinsufficiens. 
Because nicotinic acid and its metabolites are excreted through the kidneys, Trevaclyn should be used with caution in patients with renal dysfunction.
Trevaclyn bør anvendes med forsigtighed hos patienter, som indtager væsentlige mængder alkohol og/eller har leversygdom i anamnesen. 
Trevaclyn should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease.
I disse undersøgelser var procentdelen af patienter, der fik Trevaclyn, nicotinsyre (depotformuleringer, poolede) eller placebo/simvastatin (poolet), og som stoppede behandlingen på grund af flushing-relaterede symptomer (rødme, varme, kløe og prikken i huden) henholdsvis 7,2 %, 16,6 % og 0,4 %. 
In these studies, the percentage of patients taking Trevaclyn, nicotinic acid (pooled prolonged-release formulations) or pooled placebo/simvastatin who discontinued due to any flushing-related symptom (redness, warmth, itching and tingling) was 7.2 %, 16.6 %, and 0.4 %, respectively.
Ikke kendt: hyppigheden kan ikke vurderes ud fra tilgængelige data Desuden er der efter markedsføring rapporteret om en pludselig alvorlig allergisk reaktion (anafylaktisk chok) med Trevaclyn og/eller andre nicotinsyrepræparater (alene og/eller sammen med visse andre kolesterolsænkende lægemidler). 
Not known: frequency cannot be estimated from the available data Additionally, the following were reported during post-marketing experience with Trevaclyn and/or other nicotinic acid products (alone and/or with certain other cholesterol-lowering medicines).
Kosttilskud med nicotinsyre: Vitaminer eller andre ernæringstilskud med (≥ 50 mg /dag) nicotinsyre (eller nicotinamid) er ikke blevet undersøgt sammen med Trevaclyn. 
Supplements containing nicotinic acid: Vitamins or other nutritional supplements containing (≥ 50 mg/day) of nicotinic acid (or nicotinamide) have not been studied with Trevaclyn.
I tre store kliniske undersøgelser, hvor patientrapporterede flushing-symptomer blev målt, oplevede de patienter, der tog Trevaclyn, mindre flushing end de patienter, der tog nicotinsyre (depotformuleringer). 
In three large clinical trials measuring patient-reported flushing symptoms, patients taking Trevaclyn experienced less flushing than those taking nicotinic acid (prolonged-release formulations).
Trevaclyn må ikke anvendes under graviditet, med mindre det er klart nødvendigt. 
Trevaclyn is not recommended in pregnancy unless clearly necessary.
Skift fra nicotinsyre med umiddelbar udløsning (krystallinsk) til Trevaclyn er ikke undersøgt. 
Switching from immediate-release (crystalline) nicotinic acid to Trevaclyn has not been studied.
Hvis en forhøjelse i alaninaminotransferase (ALAT) eller aspartataminotransferase (ASAT) af ≥ 3 x ULN (øvre normalgrænse) varer ved, bør Trevaclyn reduceres eller seponeres. 
Should an increase in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥ 3 X ULN persist, reduction of dose or withdrawal of Trevaclyn is recommended.
Trevaclyn kan anvendes som monoterapi hos patienter, hvor HMG-CoA-reduktasehæmmere anses for at være uhensigtsmæssige eller ikke tåles. 
It can be used as monotherapy only in patients in whom HMG-CoA reductase inhibitors are considered inappropriate or not tolerated.
Trevaclyn er indiceret til behandling af dyslipidæmi, især hos voksne patienter med kombineret dyslipidæmi (karakteriseret ved forhøjede koncentrationer af LDL-kolesterol og triglycerider samt lavt HDL-kolesterol) og hos voksne patienter med primær hyperkolesterolæmi (heterozygot familiær og non-familiær). 
Trevaclyn is indicated for the treatment of dyslipidaemia, particularly in adult patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
Det skal De vide, før De begynder at tage Trevaclyn 
What you need to know before you take Trevaclyn
Et randomiseret, dobbeltblindet, placebokontrolleret 32-ugers multicenterstudie til at vurdere virkningen af seponering af laropiprant viste, at patienter med dyslipidæmi, hvor laropiprant blev seponeret efter 20 uger på Trevaclyn, oplevede signifikant mere flushing end patienter, som fortsatte med at tage Trevaclyn i form af antal dage pr. uge med moderat eller mere udbredt flushing, p<0,01, figur 2. 
A multicenter, randomized, double-blind, placebo-controlled 32-week study to assess the effects of withdrawal of laropiprant showed that dyslipidaemic patients in whom laropiprant was withdrawn after 20 weeks on Trevaclyn experienced significantly more flushing than patients who continued taking Trevaclyn in terms of number of days per week with moderate or greater flushing, p< 0.001, Figure 2.
Trevaclyn indeholder et sukkerstof, der kaldes lactose. 
Trevaclyn contains a sugar called lactose.
I den anden undersøgelse (16 uger), hvor acetylsalicylsyre var tilladt, oplevede de patienter, der fik Trevaclyn, signifikant færre dage pr. uge med moderat eller mere udbredt flushing sammenlignet med nicotinsyre (taget som depotformulering med multi-step titrering fra 500 mg til 2.000 mg over 12 uger) (p < 0,001). 
In the second study (16 weeks) where acetylsalicylic acid was allowed, patients taking Trevaclyn experienced significantly fewer days per week with moderate or greater flushing compared to nicotinic acid (prolonged-release formulation taken as a 12-week multi-step 500 mg to 2,000 mg titration) (p< 0.001).
I kontrollerede kliniske undersøgelser var incidensen af klinisk relevante stigninger i serumtransaminaser (ALAT og/eller ASAT ≥ 3 x ULN (øvre normalgrænse) konsekutivt) 1,0 % for patienter, der blev behandlet med Trevaclyn med eller uden et statin. 
In controlled clinical studies, the incidence of clinically important elevations in serum transaminases (ALT and/or AST ≥ 3 X ULN, consecutive) was 1.0 % for patients treated with Trevaclyn with or without a statin.
Pædiatrisk population Trevaclyn: Der er ikke udført undersøgelser med børn. 
Paediatric population Trevaclyn: No studies have been performed in paediatric patients.
Det Europæiske Lægemiddelagentur har udsat forpligtelsen til at fremlægge resultaterne af studier med Trevaclyn hos pædiatriske patienter i alderen 7-18 år med heterozygot familiær hyperkolesterolæmi (se pkt. 
The European Medicines Agency has deferred the obligation to submit the results of studies with Trevaclyn in paediatric patients from 7-18 years old in heterozygous familial hypercholesterolaemia (see section 4.2 for information on paediatric use).
Lægen bør overveje indtaget af nicotinsyre fra vitaminer og enæringstilskud, når Trevaclyn ordineres. 
Physicians should consider the nicotinic acid intake from vitamins and nutritional supplements when prescribing Trevaclyn.
Yderligere analyse viste, at Trevaclyn (2.000 mg/40 mg) administreret sammen med simvastatin, i sammenligning med simvastatin alene, øgede apo-A-I signifikant (henholdsvis 8,6 %, 2,3 %) og reducerede Lp(a) signifikant (henholdsvis -19,8 %, 0,0 %). 
Further analysis showed Trevaclyn (2000 mg/40 mg) co-administered with simvastatin when compared with simvastatin alone significantly increased apo A-I (8.6 %, 2.3 % respectively) and significantly decreased Lp(a) (-19.8 %, 0.0 % respectively ).
Forsigtighed bør udvises, når Trevaclyn administreres sammen med lægemidler, der overvejende metaboliseres af UGT2B4 eller UGT2B7, f.eks. zidovudin. 
Caution should be used when Trevaclyn is co-administered with medicinal products metabolised predominantly by UGT2B4 or UGT2B7, for instance zidovudine.
Da risikoen for myopati er dosisrelateret, bør Trevaclyn ikke gives sammen med simvastatin 80 mg eller ezetimibe/simvastatin 10 mg/80 mg til kinesiske patienter. 
Because the risk of myopathy with statins is dose-related, the use of Trevaclyn with simvastatin 80 mg or ezetimibe/simvastatin 10/80 mg is not recommended in Chinese patients.
Det er ukendt, om Trevaclyn går over i modermælken. 
It is not known if Trevaclyn will pass into your breast milk.
Der er ikke udført undersøgelser med Trevaclyn hos diegivende dyr. 
No studies in lactating animals have been conducted with Trevaclyn.
Der er ingen forskel i nicotinsyres perorale biotilgængelighed hos mænd og kvinder, der får Trevaclyn. 
There is no difference in the oral bioavailability of nicotinic acid in men and women receiving Trevaclyn.
Hos raske forsøgspersoner, der fik Trevaclyn, havde forudgående behandling med acetylsalicylsyre 325 mg ingen yderligere gavnlig effekt på reduktionen af nicotinsyreinducerede flushing-symptomer sammenlignet med Trevaclyn alene (se pkt. 
In healthy subjects receiving Trevaclyn, pretreatment with acetylsalicylic acid 325 mg had no additional beneficial effects in reducing nicotinic acid-induced flushing symptoms compared to Trevaclyn alone (see section 4.8).
Hver tablet med modificeret udløsning er kapselformet, hvid til off-white, med "552" præget på den ene side. 
What Trevaclyn looks like and contents of the pack Each modified-release tablet is a capsule-shaped, white to off-white tablet, with “552” debossed on one side.
Som med andre nicotinsyrepræparater er Trevaclyn blevet forbundet med små fald i fosfor. 
As with other nicotinic acid medicinal products, Trevaclyn was associated with small decreases in phosphorus levels.
Der sås klinisk relevante stigninger i kreatinkinase (≥ 10 x ULN) hos 0,3 % af de patienter, der blev behandlet med Trevaclyn med eller uden et statin (se pkt. 
Clinically important elevations of CK (≥ 10 X ULN) were seen in 0.3 % of the patients treated with Trevaclyn with or without a statin (see section 4.4).
Trevaclyn bruges som tillæg til diæt for at: 
Trevaclyn is used in addition to diet
● Trevaclyn ▲ Trevaclyn Æ nicotinsyre (laropiprant seponeret ved uge 21) ○ Placebo 
▲ Trevaclyn  nicotinic acid (laropiprant withdrawn at Week 21)
Trevaclyn bør anvendes sammen med HMG-CoA reduktasehæmmere (statiner), når den kolesterolsænkende effekt af monoterapi med HMG-CoA-reduktasehæmmere er utilstrækkelig. 
Trevaclyn should be used in patients in combination with HMG-CoA reductase inhibitors (statins), when the cholesterol lowering effect of HMG-CoA reductase inhibitor monotherapy is inadequate.
Som andre nicotinsyrepræparater er Trevaclyn kontraindiceret til patienter med signifikant eller uforklarlig leverinsufficiens. 
Like other nicotinic acid medicinal products, Trevaclyn is contraindicated in patients with significant or unexplained hepatic dysfunction.
• De er allergisk over for nicotinsyre, laropiprant eller et af de øvrige indholdsstoffer i Trevaclyn 
• you are allergic to nicotinic acid, to laropiprant, or to any of the other ingredients of this medicine (listed in section 6).
Patienter, der fik MK524A, nicotinsyre (depotformulering) eller placebo, tog også statiner (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % andre statiner [2,5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), 
Patients receiving Trevaclyn, nicotinic acid (prolonged-released formulation), or placebo were also taking statins (29 % atorvastatin [5-80 mg], 54 % simvastatin [10-80 mg], 17 % other statins [2.5-180 mg] (pravastatin, fluvastatin, rosuvastatin, lovastatin)), of which 9 % were also taking ezetimibe [10 mg].
Efter en dosis på 2.000 mg nicotinsyre , der blev administreret peroralt som to tabletter med modificeret udløsning af nicotinsyre/laropiprant sammen med mad, blev nicotinsyren absorberet med en mediantid til peak plasmakoncentration (Tmax) på 4 timer, gennemsnitligt areal under kurven for plasmakoncentrationen over tid (AUC0-last) på ca. 58,0 µM·t samt gennemsnitlig peakplasmakoncentration (Cmax) på ca. 20,2 µM. 
Following a 2,000 mg dose of nicotinic acid administered orally as two modified-release tablets of nicotinic acid/laropiprant with food, nicotinic acid was absorbed with a median time to peak plasma concentration (Tmax) of 4 hours, a mean area under the plasma concentration-time curve (AUC0-last) of approximately 58.0 μM·hr and a mean peak plasma concentration (Cmax) of approximately 20.2 μM.
Forsigtighed bør udvises ved behandling af kinesiske patienter med Trevaclyn i kombination med simvastatin eller ezetimibe/simvastatin (især ved simvastatindoser på 40 mg eller derover). 
Caution should be used when treating Chinese patients with Trevaclyn co-administered with simvastatin or ezetimibe/simvastatin (particularly simvastatin doses of 40 mg or higher).
• Undgå at drikke alkohol eller varme drikke og at spise krydret mad tæt på det tidspunkt, hvor De tager Trevaclyn. 
• Avoid drinking alcohol or hot drinks or eating spicy foods near the time you take your dose of Trevaclyn.
I fire aktive eller placebo-kontrollerede kliniske undersøgelser (N=4.747, n=2.548, der tog Trevaclyn) blev der af investigator rapporteret om flushing som enten en mulig, sandsynlig eller klart behandlingsrelateret bivirkning hos 12,3 % af de patienter, der fik Trevaclyn. 
In a pool of four active- or placebo-controlled clinical trials (N=4,747, n=2,548 taking Trevaclyn), flushing was reported in 12.3 % of patients taking Trevaclyn.
Der er utilstrækkelige data fra anvendelsen af højdosis-nicotinsyre til gravide kvinder. 
There are no adequate data from the use of high dose nicotinic acid in pregnant women.
Trevaclyn bør derfor anvendes med forsigtighed hos patienter, der har eller er disponeret for urinsyregigt. 
Therefore, Trevaclyn should be used with caution in patients with or predisposed to gout.
• Gå regelmæssigt til lægen for at få kontrolleret Deres LDL (det "dårlige" kolesterol) og HDL (det "gode" kolesterol) samt indholdet af triglycerider i blodet. 
• See your doctor regularly to check your LDL (bad) and HDL (good) cholesterol levels and your triglyceride level.
Ikke almindelige (kan berøre op til 1 ud af 100 personer) Desuden er en eller flere af følgende symptomer set som del af en allergisk reaktion over for Trevaclyn. 
In addition, one or more of the following symptoms have been reported as part of an allergic reaction to Trevaclyn.
Hvis De skifter fra et depotlægemiddel, der indeholder mindre end 2.000 mg nicotinsyre, skal De starte med at tage én Trevaclyn-tablet om dagen. 
If you are switching from a medicine with less than 2,000 mg of prolonged-nicotinic acid, you should start by taking one tablet of Trevaclyn a day.
Nicotinsyre, der er en af bestanddelene i Trevaclyn, går dog over i modermælken. 
However, nicotinic acid a component of Trevaclyn does pass into breast milk.
EU/1/08/458/001 14 tabletter med modificeret udløsning EU/1/08/458/002 28 tabletter med modificeret udløsning EU/1/08/458/003 56 tabletter med modificeret udløsning EU/1/08/458/004 84 tabletter med modificeret udløsning EU/1/08/458/005 98 tabletter med modificeret udløsning EU/1/08/458/006 168 tabletter med modificeret udløsning EU/1/08/458/007 196 tabletter med modificeret udløsning EU/1/08/458/008 49 x 1 tabletter med modificeret udløsning EU/1/08/458/012 196 (2 pakninger à 98) tabletter med modificeret udløsning 
EU/1/08/458/001 14 modified-release tablets EU/1/08/458/002 28 modified-release tablets EU/1/08/458/003 56 modified-release tablets EU/1/08/458/004 84 modified-release tablets EU/1/08/458/005 98 modified-release tablets EU/1/08/458/006 168 modified-release tablets EU/1/08/458/007 196 modified-release tablets EU/1/08/458/008 49 x 1 modified-release tablets EU/1/08/458/012 196 (2 packs of 98) modified-release tablets
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om fremlæggelse af resultaterne af studier med Trevaclyn hos alle undergrupper af den pædiatriske population ved homozygot familiær hyperkolesterolæmi. 
The European Medicines Agency has waived the obligation to submit the results of studies with Trevaclyn in all subsets of the paediatric population in homozygous familial hypercholesterolaemia (see section 4.2 for information on paediatric use).
Trevaclyn: Anvendelse til patienter med nyreinsufficiens er ikke undersøgt. 
Trevaclyn: Use in patients with renal insufficiency has not been studied.
Hos patienter, der fortsatte i den første undersøgelse (24 uger), aftog hyppigheden af moderat eller mere udbredt flushing hos patienter, der blev behandlet med Trevaclyn, og nærmede sig reaktionen hos de patienter, der fik placebo (se figur 1). 
In patients continuing in the first study (24 weeks), the frequency of moderate or greater flushing in patients treated with Trevaclyn declined and approached that of patients receiving placebo (see Figure 1), whereas in patients treated with nicotinic acid (prolonged-release formulation) the flushing frequency remained constant (after Week 6).
Da samtidig administration af galdesyrebindende lægemidler kan reducere biotilgængeligheden af sure lægemidler, såsom nicotinsyre, bør Trevaclyn gives >1 time før eller > 4 timer efter administration af et galdesyrebindende lægemiddel (se pkt. 
Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Trevaclyn be administered > 1 hour before or > 4 hours after administration of a bile acid sequestrant (see section 4.5).
Hvis De er i tvivl om noget af ovenstående passer på Dem, skal De tale med lægen eller apoteket, før De tager Trevaclyn. 
If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking Trevaclyn.
• Hvis De skifter fra et depotlægemiddel, der indeholder 2.000 mg nicotinsyre eller mere, kan lægen sætte Deres behandling i gang med to Trevaclyn tabletter om dagen. 
• If you are switching from a medicine containing 2,000 mg or more of a prolonged-release nicotinic acid, your doctor can start you with two tablets of Trevaclyn a day.
LÆGEMIDDELFORM OG ANTAL (PAKNINGSSTØRRELSE) 98 tabletter med modificeret udløsning. 
PHARMACEUTICAL FORM AND CONTENTS 98 modified-release tablets.
Hos rotter sås føtotoksiske virkninger (signifikant nedsat fostervægt associeret med nedsat forbening af korsbens og halehvirvler og en øget forekomst af fostre med stedvis ufuldstændig forbening af knogler) uden at der var tegn på maternel toksicitet ved eksponeringer, der var ca. 959 gange human AUC for nicotinsyre ved anbefalet daglig dosis til mennesker. 
In rats, foetotoxic effects (significantly decreased foetal body weights associated with a decrease in the number of ossified sacrocaudal vertebrae and an increased incidence of foetuses with sites of incomplete ossification) were noted in the absence of any signs of maternal toxicity at exposure levels approximately 959 times the human AUC of nicotinic acid at the recommended daily human dose.
: +420 233 010 111 msd_cr@merck.com 
Tel.: +420 233 010 111 msd_cr@merck.com
Galdesyrebindende lægemidler: Da samtidig administration af galdesyrebindende lægemidler kan reducere biotilgængeligheden af sure lægemidler, såsom nicotinsyre, anbefales det, at Trevaclyn administreres >1 time før eller > 4 timer efter administration af et galdesyrebindende lægemiddel. 
Effects of other medicinal products on nicotinic acid Bile acid sequestrants: Because co-administration of bile acid sequestrants may reduce the bioavailability of acidic medicinal products such as nicotinic acid, it is recommended that Trevaclyn be administered > 1 hour before or > 4 hours after administration of a bile acid sequestrant.